Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GSK plc has repurchased 513,409 of its ordinary shares on 11 March 2026 through BNP Paribas, at a volume‑weighted average price of 2,061.69 pence per share, with the stock to be held in treasury as part of its ongoing share buyback programme. Since the non‑discretionary arrangement began on 17 February 2026, GSK has bought back 8,690,409 shares, lifting treasury holdings to 248,581,503 shares, or 6.11% of voting rights, and leaving 4,067,587,319 voting shares in issue, information that investors can use to assess ownership thresholds and disclosure obligations.
The buyback activity underscores GSK’s continued capital return strategy and signals management’s willingness to deploy cash to reduce free‑float equity and potentially support earnings per share. The updated voting‑rights denominator will be closely watched by shareholders and regulators under UK disclosure rules, while the increasing treasury stake may influence future decisions on capital structure flexibility, such as further buybacks, potential share cancellations or use of treasury stock for corporate purposes.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on researching, developing and commercialising prescription medicines, vaccines and specialty therapies. The group targets major disease areas including infectious diseases, respiratory conditions and oncology, with a significant presence in both developed and emerging healthcare markets.
Average Trading Volume: 8,950,971
Technical Sentiment Signal: Buy
Current Market Cap: £82.75B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.